AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36595123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally once daily
Number of subjects: 35
Study 36595435 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD Compass intervention
Number of subjects: 0
Study 36595435 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 0
Study 36595449 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater elaboration of parents' schemas
Number of subjects: 242
Study 36595449 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive emotional valence of parents' schemas
Number of subjects: 242
Study 36595523 — intervention group
Group type: EXPERIMENTAL
Intervention: PEBRA model (peer educator-coordinated care)
Number of subjects: 307
Study 36595523 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic care (nurse-coordinated care)
Number of subjects: 307
Study 36595523 — intervention group
Group type: EXPERIMENTAL
Intervention: PEBRA model
Number of subjects: 307
Study 36595523 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic care
Number of subjects: 307
Study 36595537 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load (VL)
Number of subjects: 2650
Study 36595537 — intervention group
Group type: EXPERIMENTAL
Intervention: Shannon entropy at AA positions
Number of subjects: 2650
Study 36595537 — intervention group
Group type: COMPARATOR
Intervention: HIV consensus sequences
Number of subjects: 2650
Study 36595540 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant targeted therapy (EGFR inhibitors and anti-ErbB3 antibody therapy)
Number of subjects: 92
Study 36595540 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant targeted therapy
Number of subjects: 92
Study 36595569 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab with standard chemotherapy and bevacizumab
Number of subjects: 1050
Study 36595569 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standard chemotherapy and bevacizumab
Number of subjects: 1050
Study 36596223 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm muscle strength training
Number of subjects: 0
Study 36596223 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 36596347 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic classifier (GC) scores obtained from biopsy samples
Number of subjects: 385
Study 36596439 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered, multidimensional bladder health scales and function indices (paper and electronic forms)
Number of subjects: 1072
Study 36596443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried blood spot (DBS) collections
Number of subjects: 294
Study 36596609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone preparations
Number of subjects: 0
Study 36596632 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic stationary cycling three times per week with graded virtual supervision
Number of subjects: 60
Study 36596632 — intervention group
Group type: COMPARATOR
Intervention: Monthly virtual MS symptom education groups (six sessions)
Number of subjects: 60
Study 36596634 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, multimodal, multidisciplinary prehabilitation programme over 2-4 weeks addressing deficits in physical fitness and nutrition, diabetes control, correction of anaemia and smoking cessation.
Number of subjects: 466
Study 36596634 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 466
Study 36596653 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 0
Study 36596653 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 0
Study 36596656 — intervention group
Group type: EXPERIMENTAL
Intervention: Left carotid artery (CA)
Number of subjects: 540
Study 36596656 — intervention group
Group type: COMPARATOR
Intervention: Right carotid artery (CA)
Number of subjects: 540
Study 36596682 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate empirical antibiotics
Number of subjects: 155
Study 36596682 — intervention group
Group type: COMPARATOR
Intervention: Inappropriate empirical antibiotics
Number of subjects: 155
Study 36596692 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36596787 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of immune checkpoint inhibitor (camrelizumab), antiangiogenesis (apatinib), and chemotherapy (S-1 ± oxaliplatin)
Number of subjects: 0
Study 36596867 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation initiated at ≤ 4 days after EVT
Number of subjects: 234
Study 36596867 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation initiated at ≥ 15 days after EVT
Number of subjects: 234
Study 36596867 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation initiated between 4 to 15 days after EVT
Number of subjects: 234
Study 36596867 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation initiation time longer than 4.5 days
Number of subjects: 234
Study 36596867 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation initiation time earlier than 4.5 days
Number of subjects: 234
Study 36596867 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable outcome (mRS 0-1) at 90 days
Number of subjects: 234
Study 36596867 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic intracranial hemorrhage (sICH) after anticoagulants
Number of subjects: 234
Study 36596867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhage (ICH) after anticoagulants
Number of subjects: 234
Study 36596867 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic hemorrhage after anticoagulants
Number of subjects: 234
Study 36596908 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 331
Study 36596908 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 331
Study 36596945 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal therapy with mother's own milk (OPT-MOM)
Number of subjects: 220
Study 36596945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 36597036 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 796
Study 36597036 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 3 comorbidities
Number of subjects: 796
Study 36597036 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 1 geriatric syndrome
Number of subjects: 796
Study 36597036 — intervention group
Group type: COMPARATOR
Intervention: Nothing (no frailty, comorbidities, or geriatric syndromes)
Number of subjects: 796
Study 36597036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 796
Study 36597036 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 796
Study 36597074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lolli-Methode (LM) for epidemiological surveillance and early intervention
Number of subjects: 8800
Study 36597074 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) surveillance by public health departments
Number of subjects: 8800
Study 36597074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lolli-Methode (LM)
Number of subjects: 8800
Study 36597074 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 8800
Study 36597076 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ferroquine plus artefenomel 300 mg
Number of subjects: 140
Study 36597076 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ferroquine plus artefenomel 600 mg
Number of subjects: 140
Study 36597076 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ferroquine plus artefenomel 1000 mg
Number of subjects: 140
Study 36597076 — intervention group
Group type: COMPARATOR
Intervention: 400 mg ferroquine
Number of subjects: 140
Study 36597103 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid injection into the infrapatellar fat pad (IPFP)
Number of subjects: 60
Study 36597103 — intervention group
Group type: COMPARATOR
Intervention: Saline injection into the infrapatellar fat pad (IPFP)
Number of subjects: 60
Study 36597110 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (< 72 hours) in 'Young Trauma' patients
Number of subjects: 948
Study 36597110 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-based clustering for mobilization recommendations
Number of subjects: 948
Study 36597115 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-dose azithromycin (AZI)
Number of subjects: 0
Study 36597115 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose azithromycin (AZI)
Number of subjects: 0
Study 36597115 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 36597120 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who had given birth
Number of subjects: 1069
Study 36597120 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who recalled severe, acute postpartum back pain
Number of subjects: 1069
Study 36597120 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute postpartum back pain
Number of subjects: 1069
Study 36597128 — intervention group
Group type: EXPERIMENTAL
Intervention: AFM11 in patients with R/R NHL (AFM11-101)
Number of subjects: 33
Study 36597128 — intervention group
Group type: EXPERIMENTAL
Intervention: AFM11 in patients with R/R ALL (AFM11-102)
Number of subjects: 33
Study 36597136 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based resilience programme signposted by clinicians during antenatal consultations
Number of subjects: 2100
Study 36597136 — intervention group
Group type: COMPARATOR
Intervention: Standard preventive consultations without web-based resource signposting
Number of subjects: 2100
Study 36597145 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Dynamic Activation (MDA)
Number of subjects: 90
Study 36597145 — intervention group
Group type: COMPARATOR
Intervention: EDDY
Number of subjects: 90
Study 36597145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EDDY and MDA
Number of subjects: 90
Study 36597163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg/kg and ketamine 3 mg/kg
Number of subjects: 136
Study 36597163 — intervention group
Group type: COMPARATOR
Intervention: Oral chloral hydrate 50 mg/kg
Number of subjects: 136
Study 36597183 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanvir program with dedicated screening days and innovative screening technologies (RDTs, FibroScan®, point-of-care HCV RNA testing)
Number of subjects: 392
Study 36597183 — intervention group
Group type: EXPERIMENTAL
Intervention: RDTs
Number of subjects: 392
Study 36597183 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroScan®
Number of subjects: 392
Study 36597183 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroScan® for advanced fibrosis evaluation
Number of subjects: 392
Study 36597186 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 51
Study 36597186 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study 36597274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition of exercise in hemodialysis patients (active vs inactive)
Number of subjects: 505
Study 36597274 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to exercise in hemodialysis patients
Number of subjects: 505
Study 36597274 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise during hemodialysis for inactive patients
Number of subjects: 505
Study 36597480 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress urinary incontinence (SUI)
Number of subjects: 4208
Study 36597543 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,500mg per day for 14 days)
Number of subjects: 1125
Study 36597543 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin (430mcg/kg/day for 3 days)
Number of subjects: 1125
Study 36597543 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (50mg on day one then 50mg twice daily through 14 days)
Number of subjects: 1125
Study 36597719 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 5971
Study 36597795 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP2 levels
Number of subjects: 65
Study 36598543 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg CBD
Number of subjects: 70
Study 36598543 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg CBD
Number of subjects: 70
Study 36598543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 36598575 — intervention group
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Number of subjects: 0
Study 36598602 — intervention group
Group type: EXPERIMENTAL
Intervention: Total 25-hydroxyvitamin D levels in periodontitis patients
Number of subjects: 39
Study 36598602 — intervention group
Group type: EXPERIMENTAL
Intervention: Free 25-hydroxyvitamin D levels in periodontitis patients
Number of subjects: 39
Study 36598602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailable 25-hydroxyvitamin D levels in periodontitis patients
Number of subjects: 39
Study 36598602 — intervention group
Group type: COMPARATOR
Intervention: Total 25-hydroxyvitamin D levels
Number of subjects: 39
Study 36598602 — intervention group
Group type: COMPARATOR
Intervention: Free 25-hydroxyvitamin D levels
Number of subjects: 39
Study 36598602 — intervention group
Group type: COMPARATOR
Intervention: Bioavailable 25-hydroxyvitamin D levels
Number of subjects: 39
Study 36598621 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTV01E vaccine
Number of subjects: 0
Study 36598621 — intervention group
Group type: COMPARATOR
Intervention: D614G monovalent vaccine
Number of subjects: 0
Study 36598690 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contrast coronary MRA (NC-MRCA) with stenosis
Number of subjects: 0
Study 36598690 — intervention group
Group type: COMPARATOR
Intervention: Non-contrast coronary MRA (NC-MRCA) without stenosis
Number of subjects: 0
Study 36598761 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation intervention
Number of subjects: 337
Study 36598761 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 337
Study 36598770 — intervention group
Group type: EXPERIMENTAL
Intervention: Active screening with population-based electronic screening and targeted clinician education.
Number of subjects: 4887
Study 36598770 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) with clinician education alone.
Number of subjects: 4887
Study 36599056 — intervention group
Group type: EXPERIMENTAL
Intervention: Soapp app with various combinations of habit, motivation, and social norms modules (9 conditions)
Number of subjects: 232
Study 36599056 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis from thematic analysis of exit interviews
Number of subjects: 232
Study 36599114 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab in combination with lenalidomide and dexamethasone (D-Rd)
Number of subjects: 0
Study 36599114 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 0
Study 36599120 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-IGABT with external beam radiotherapy and concurrent chemotherapy
Number of subjects: 1318
Study 36599120 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-IGABT
Number of subjects: 1318
Study 36599120 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 1318
Study 36599136 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF + PegIFN (n = 102)
Number of subjects: 201
Study 36599136 — intervention group
Group type: COMPARATOR
Intervention: TDF alone (n = 99)
Number of subjects: 201
Study 36599136 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF + PegIFN
Number of subjects: 201
Study 36599136 — intervention group
Group type: COMPARATOR
Intervention: TDF alone
Number of subjects: 201
Study 36599304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary macronutrient composition modulation according to MIR phenotype
Number of subjects: 242
Study 36599304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary macronutrient composition modulation according to LIR phenotype
Number of subjects: 242
Study 36599321 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of Mg
Number of subjects: 1245
Study 36599321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1245
Study 36599321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower serum Mg level (<1.7 mg/dL) posttreatment
Number of subjects: 1245
Study 36599321 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal serum Mg level (≥1.7 mg/dL) posttreatment
Number of subjects: 1245
Study 36599332 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip intervention in NYHA Class IV patients
Number of subjects: 1041
Study 36599549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val) therapy
Number of subjects: 416
Study 36599553 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263
Study 36599553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study 36599567 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular ejection fraction (RVEF)
Number of subjects: 736
Study 36599567 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular edema
Number of subjects: 736
Study 36599567 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular late gadolinium enhancement (RV-LGE)
Number of subjects: 736
Study 36599567 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint of major adverse cardiovascular events (MACE)
Number of subjects: 736
Study 36599584 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month DAPT followed by clopidogrel monotherapy
Number of subjects: 2030
Study 36599584 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT with aspirin and clopidogrel
Number of subjects: 2030
Study 36599584 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy after 1-month DAPT
Number of subjects: 2030
Study 36599637 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations and psychological factors
Number of subjects: 300
Study 36599637 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews and ambulatory assessments
Number of subjects: 300
Study 36599699 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic deficits (measured by NIH Stroke Scale [NIHSS])
Number of subjects: 525
Study 36599699 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb paresis
Number of subjects: 525
Study 36599699 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphasia
Number of subjects: 525
Study 36599699 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemianopia
Number of subjects: 525
Study 36599699 — intervention group
Group type: EXPERIMENTAL
Intervention: Neglect
Number of subjects: 525
Study 36599698 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NF-L
Number of subjects: 118
Study 36599698 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum GFAP
Number of subjects: 118
Study 36599698 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF NF-L
Number of subjects: 118
Study 36599698 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF GFAP
Number of subjects: 118
Study 36599736 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV 239 vaccine (two doses at 0 and 1 month)
Number of subjects: 100
Study 36599736 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV 239 vaccine
Number of subjects: 100
Study 36599736 — intervention group
Group type: COMPARATOR
Intervention: Control (Hepatitis B virus vaccine)
Number of subjects: 100
Study 36599966 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported discrimination
Number of subjects: 1533
Study 36599966 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater perceived psychosocial support
Number of subjects: 1533
Study 36599966 — intervention group
Group type: COMPARATOR
Intervention: FGM/C status
Number of subjects: 1533
Study 36599966 — intervention group
Group type: COMPARATOR
Intervention: Discrimination (reported among 'No FGM/C' women)
Number of subjects: 1533
Study 36600099 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT using a PSMA-specific tracer
Number of subjects: 42
Study 36600099 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 42
Study 36600109 — intervention group
Group type: EXPERIMENTAL
Intervention: aducanumab
Number of subjects: 0
Study 36600109 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 36600178 — intervention group
Group type: EXPERIMENTAL
Intervention: ustekinumab
Number of subjects: 895
Study 36600178 — intervention group
Group type: COMPARATOR
Intervention: TNF inhibitors (TNFi)
Number of subjects: 895
Study 36600185 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day
Number of subjects: 4362
Study 36600185 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg two times per day
Number of subjects: 4362
Study 36600185 — intervention group
Group type: COMPARATOR
Intervention: TNF inhibitors (TNFi)
Number of subjects: 4362
Study 36600185 — intervention group
Group type: EXPERIMENTAL
Intervention: combined tofacitinib doses
Number of subjects: 4362
Study 36600185 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 4362
Study 36600247 — intervention group
Group type: EXPERIMENTAL
Intervention: HL-085 (12 mg twice daily)
Number of subjects: 42
Study 36600247 — intervention group
Group type: EXPERIMENTAL
Intervention: HL-085 (up to 18 mg twice daily)
Number of subjects: 42
Study 36600247 — intervention group
Group type: EXPERIMENTAL
Intervention: HL-085 (all doses)
Number of subjects: 42
Study 36600262 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions (PI): psychoeducation, problem-solving, and rehearsal strategies for 5 weeks
Number of subjects: 50
Study 36600262 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=25)
Number of subjects: 50
Study 36600280 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio Messaging/Video Job Aids/Early Child Development (RMV-ECD)
Number of subjects: 0
Study 36600280 — intervention group
Group type: COMPARATOR
Intervention: Radio Messaging (RM)
Number of subjects: 0
Study 36600302 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents Together program (intervention group)
Number of subjects: 0
Study 36600302 — intervention group
Group type: COMPARATOR
Intervention: Usual health care (control group)
Number of subjects: 0